Assembly Bill A9634

2019-2020 Legislative Session

Relates to medication assisted treatment for substance use disorders

download bill text pdf

Sponsored By

Archive: Last Bill Status - In Assembly Committee


  • Introduced
    • In Committee Assembly
    • In Committee Senate
    • On Floor Calendar Assembly
    • On Floor Calendar Senate
    • Passed Assembly
    • Passed Senate
  • Delivered to Governor
  • Signed By Governor

Do you support this bill?

Please enter your contact information

Home address is used to determine the senate district in which you reside. Your support or opposition to this bill is then shared immediately with the senator who represents you.

Optional services from the NY State Senate:

Create an account. An account allows you to officially support or oppose key legislation, sign petitions with a single click, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.

Include a custom message for your Senator? (Optional)

Enter a message to your senator. Many New Yorkers use this to share the reasoning behind their support or opposition to the bill. Others might share a personal anecdote about how the bill would affect them or people they care about.
Actions

co-Sponsors

2019-A9634 (ACTIVE) - Details

See Senate Version of this Bill:
S7699
Current Committee:
Assembly Ways And Means
Law Section:
Social Services Law
Laws Affected:
Amd §§365-a & 364-j, Soc Serv L; amd §273, Pub Health L
Versions Introduced in 2021-2022 Legislative Session:
A2030, S649

2019-A9634 (ACTIVE) - Summary

Relates to medication assisted treatment for substance abuse disorders; prohibits prior authorization.

2019-A9634 (ACTIVE) - Bill Text download pdf

                            
 
                     S T A T E   O F   N E W   Y O R K
 ________________________________________________________________________
 
                                   9634
 
                           I N  A S S E M B L Y
 
                             January 28, 2020
                                ___________
 
 Introduced by M. of A. L. ROSENTHAL, QUART, RICHARDSON, CARROLL, WEPRIN,
   SIMON, GOTTFRIED, HEVESI -- read once and referred to the Committee on
   Health
 
 AN  ACT  to  amend the social services law and the public health law, in
   relation to medication for the treatment of substance use disorders
 
   THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND  ASSEM-
 BLY, DO ENACT AS FOLLOWS:
 
   Section  1.  Subdivision 2 of section 365-a of the social services law
 is amended by adding a new paragraph (gg) to read as follows:
   (GG) ALL BUPRENORPHINE PRODUCTS, METHADONE OR LONG  ACTING  INJECTABLE
 NALTREXONE  FOR  DETOXIFICATION  OR MAINTENANCE TREATMENT OF A SUBSTANCE
 USE DISORDER PRESCRIBED ACCORDING TO GENERALLY ACCEPTED NATIONAL PROFES-
 SIONAL GUIDELINES FOR THE TREATMENT OF A SUBSTANCE USE DISORDER.    SUCH
 MEDICATION ASSISTED TREATMENT SHALL NOT BE SUBJECT TO ANY PRIOR AUTHORI-
 ZATION MANDATE.
   §  2. Subdivision 26-b of section 364-j of the social services law, as
 added by section 4 of part B of chapter 69  of  the  laws  of  2016,  is
 amended to read as follows:
   26-b. Managed care providers shall not require prior authorization for
 [an  initial  or  renewal  prescription  for buprenorphine or injectable
 naltrexone  for  detoxification  or  maintenance  treatment  of   opioid
 addiction  unless  the prescription is for a non-preferred or non-formu-
 lary form of the drug or as otherwise required by section 1927(k)(6)  of
 the  Social  Security Act] ANY BUPRENORPHINE PRODUCTS, METHADONE OR LONG
 ACTING INJECTABLE NALTREXONE FOR DETOXIFICATION OR MAINTENANCE TREATMENT
 OF A SUBSTANCE USE DISORDER PRESCRIBED ACCORDING TO  GENERALLY  ACCEPTED
 NATIONAL  PROFESSIONAL  GUIDELINES  FOR THE TREATMENT OF A SUBSTANCE USE
 DISORDER.
   § 3. Subdivision 10 of section 273 of the public health law, as  added
 by  section 5 of part B of chapter 69 of the laws of 2016, is amended to
 read as follows:
   10. Prior authorization shall not  be  required  for  [an  initial  or
 renewal  prescription  for  buprenorphine  or  injectable naltrexone for
 detoxification or maintenance treatment of opioid addiction  unless  the

  EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
              

Comments

Open Legislation is a forum for New York State legislation. All comments are subject to review and community moderation is encouraged.

Comments deemed off-topic, commercial, campaign-related, self-promotional; or that contain profanity, hate or toxic speech; or that link to sites outside of the nysenate.gov domain are not permitted, and will not be published. Attempts to intimidate and silence contributors or deliberately deceive the public, including excessive or extraneous posting/posts, or coordinated activity, are prohibited and may result in the temporary or permanent banning of the user. Comment moderation is generally performed Monday through Friday. By contributing or voting you agree to the Terms of Participation and verify you are over 13.

Create an account. An account allows you to sign petitions with a single click, officially support or oppose key legislation, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.